Linked Life Data

10788594

Source:http://linkedlifedata.com/resource/pubmed/id/10788594

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2000-6-2
pubmed:abstractText
Antiviral therapy of chronic hepatitis B remains a major clinical problem worldwide. The design of new nucleoside analogs that inhibit hepatitis B virus (HBV) replication allowed their evaluation in in vitro and in vivo experimental models of HBV infection. This research has led to the discovery of the anti-HBV activity of lamivudine and its approval for the therapy of chronic hepatitis B. However, due to the development of viral resistance, strategies based on the combination of new inhibitors of HBV replication with immune modulatory approaches are urgently required.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1381-6128
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
503-23
pubmed:dateRevised
2006-2-27
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Design and evaluation of hepatitis B virus inhibitors.
pubmed:affiliation
INSERM Unit 271, 151 cours Albert Thomas, Lyon, 69003, France.
pubmed:publicationType
Journal Article, Review